Samira Asma

Samira Asma

Auto-generated profile, based on publicly available information

Samira Asma

Rockefeller Foundation-Boston University 3-D Commission on Determinants, Data, and Decision-making, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in The Lancet
Verified
Journal Article
Closed access
SASamira Asma
Samira Asma
RLRafael Lozano
Rafael Lozano
SCSomnath Chatterji
Somnath Chatterji
SSSoumya Swaminathan
Soumya Swaminathan
MMMaria de Fátima Marinho
Maria de Fátima Marinho
CMChristopher J L Murray
Christopher J L Murray

15 January 2019 in International Journal for Equity in Health
Verified
Journal Article
Open access
PDF file
BDBiplab Datta
Biplab Datta
MHMuhammad Jami Husain
Muhammad Jami Husain
SASamira Asma
Samira Asma
Treatment of non-communicable diseases (NCDs) in low-and-middle-income countries (LMICs) is costly and could expose households to financial hardship and vulnerability. This paper examines the association between medication costs of two major NCDs – hypertension (blood pressure) and diabetes, and household-level incidences of catastrophic health expenditure (CHE) in a South Asian LMIC, Pakistan. The study analyzes self-reported blood pressure and diabetes (BPD) medication expenditure from the latest version (2015–16) of the Household Integrated Economic Survey (HIES) of Pakistan, a nationally representative survey of 24,238 households. The incidence of CHE is defined as households’ out-of-pocket (OOP) medical expenditure exceeding 10% of the total household expenditure. Using a linear probability model, we estimate the adjusted differences in CHE incidence between households that are spending and ‘not’ spending on BPD medication. We also analyze several hypothetical scenarios of BPD medication cost coverage, and compare the estimated CHE incidences of respective scenarios with the status quo. We find that the average monthly medical expenditure, and average medical expenditure share are significantly higher for households spending on BPD medication, compared to households ‘not’ spending. The incidence of CHE is found 6.7 percentage point higher for the households consuming BPD medication, after controlling for relevant socioeconomic attributes. If 25, 50, and 100% of the BPD medication OOP cost is covered, then the CHE incidence would reduce respectively by 5.9, 12.7, and 21.4% compared to the status quo. Medication cost for managing two major NCDs and household catastrophic health expenditure have strong associations. The findings inform policies toward ensuring access to necessary healthcare services, and protecting households from NCD treatment related financial hardship.

18 August 2021 in Journal of Urban Health
Verified
Journal Article
Closed access
PDF file
BTBishnu Thapa
Bishnu Thapa
ITIrene Torres
Irene Torres
SKShaffi Fazaludeen Koya
Shaffi Fazaludeen Koya
GRGrace Robbins
Grace Robbins
SASalma M. Abdalla
Salma M. Abdalla
HLHeidi Larson
Heidi Larson

1 August 2021 in Journal of Urban Health
Verified
Journal Article
Closed access
PDF file
ITIrene Torres
Irene Torres
BTBishnu Thapa
Bishnu Thapa
GRGrace Robbins
Grace Robbins
SKShaffi Fazaludeen Koya
Shaffi Fazaludeen Koya
SASalma M Abdalla
Salma M Abdalla
KRKyu Rhee
Kyu Rhee